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Background: The Australian Aboriginal population experiences disproportionately high rates of otitis
media (OM). Streptococcus pneumoniae is one of the main pathogens responsible for OM and currently no
vaccine offering cross strain protection exists. Vaccines consisting of conserved antigens to S. pneumoniae
may reduce the burden of OM in high-risk populations; however no data exists examining naturally
acquired antibody in Aboriginal children with OM.
Methods: Serum and salivary IgA and IgG were measured against the S. pneumoniae antigens PspA1 and
2, CbpA and Ply in a cross sectional study of 183 children, including 36 non-Aboriginal healthy control
children and 70 Aboriginal children and 77 non-Aboriginal children undergoing surgery for OM using a
multiplex bead assay.
Results: Signiﬁcant differences were observed between the 3 groups for serum anti-PspA1 IgA, anti-CbpA
and anti-Ply IgG and for all salivary antibodies assessed. Aboriginal children with a history of OM had
signiﬁcantly higher antibody titres than non-Aboriginal healthy children with no history of OM and non-
Aboriginal children with a history of OM for several proteins in serum and saliva. Non-Aboriginal chil-
drenwith a history of OM had signiﬁcantly higher salivary anti-PspA1 IgG than healthy children, while all
other titres were comparable between the groups.
Conclusions: Conserved vaccine candidate proteins from S. pneumoniae induce serum and salivary
antibody responses in Aboriginal and non-Aboriginal children with a history of OM. Aboriginal children
do not have an impaired antibody response to the antigens measured from S. pneumoniae and they may
represent vaccine candidates in Indigenous populations.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).stralia, School of Paediatrics
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Australian Aboriginal children suffer from disproportionately
high rates of otitis media (OM) in comparison with their non-
Aboriginal counterparts [1]. Some of the highest reported rates of
OM in the world are in those Aboriginal children living in remote
areas of Australia, where more than 90% of children have evidence
of OM, and up to 40% of children are reported to have tympanic
membrane perforation at any given time [2e4]. The World Health
Organization has stated that regions with a prevalence of tympanic
membrane perforations of 4% or more have a signiﬁcant public
health problem, requiring urgent attention [5]. OM in Australianarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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prolonged and severe than in non-Aboriginal children [6e8]. In-
fections will often persist throughout childhood and the middle ear
rarely normalizes [9]. The high rates of OM experienced by
Aboriginal children are associated with moderate to severe hearing
loss and long-term complications [10] that impact on speech, lan-
guage development and education, and may result in serious
sequelae such as cholesteatoma, meningitis and permanent hear-
ing loss [11e13].
Despite the introduction of pneumococcal conjugate vaccina-
tion for all Australian Aboriginal children in 2001, Streptococcus
pneumoniae is still a common OM pathogen [4]. High levels of
antibiotic resistance have been reported in pneumococcal isolates
from Aboriginal children and most serotypes identiﬁed are not
covered by any of the currently licensed vaccines [4,14]. Protein-
based vaccines may offer serotype-independent protection
against the pneumococcus and are the subject of intense research.
Several pneumococcal proteins are in early clinical trials to assess
whether they confer protection against pneumococcal carriage and
transmission or mucosal and systemic diseases [15]. Anti-protein
antibodies are important (along with cellular immune responses)
in protection from the pneumococcus by either blocking patho-
genic mechanisms or through opsonisation of the bacteria [15].
Three pneumococcal proteins that are currently under investiga-
tion as vaccine candidates are pneumococcal surface protein A
(PspA), pneumolysin (Ply), and choline binding protein A (CbpA)
[15e17]. There is a paucity of data assessing the development of
natural immunity to pneumococcal proteins in children, particu-
larly in Indigenous populations that are at high risk of pneumo-
coccal disease.
Otitis-prone children have been described as having impaired
humoral immune responses to the major otopathogens, leading to
recurrent infections [18,19]. However, data from our laboratory and
others found that childrenwith a history of chronic or recurrent OM
have similar antigen-speciﬁc antibody responses to pneumococcal
proteins and polysaccharides, including those in the pneumococcal
conjugate vaccinewhen compared to healthy children [20e26]. It is
unknown if the differences observed in these studies reﬂect dif-
ferences in assays, study design or the populations studied. Similar
IgG titres to pneumococcal polysaccharide and conjugate vaccines
have been described in Aboriginal and non-Aboriginal populations
[27], suggesting no impairment in polysaccharide responses in
Aboriginal populations. Aboriginal babies were found to have
higher cord-blood IgG titres (to 6 of the 12 pneumococcal serotypes
tested) and higher avidity (for 4 of the 8 serotypes tested) than
Gambian infants who have similar rates of early pneumococcal
colonisation without the high rates of OM [28]. No data exists on
the levels of naturally acquired pneumococcal protein antibodies in
Australian Aboriginal children and this is important in considering
potential protein vaccine studies. This study investigated the
naturally acquired antibody titres to potential pneumococcal vac-
cine antigens in Aboriginal children undergoing surgery for OM and
compared these to age-matched non-Aboriginal children with OM
and healthy controls. It is important to measure baseline immunity
to vaccine candidates, particularly in high-risk populations, to
determine the suitability of each antigen for inclusion in a vaccine.
2. Methods
2.1. Patient populations
2.1.1. Otitis media cases
Children aged between 1 and 15 years were recruited at time of
admission for tympanoplasty or ventilation tube insertion through
public hospitals in urban and remote West Australian hospitalsduring 2003e2008. Written informed consent was obtained from
parents or guardians. Clinical data was collected using parental
questionnaires and medical records. Childrenwere included if they
met clinical criteria to undergo ventilation tube insertion for either
otitis media with effusion (OME) or recurrent acute otitis media
(rAOM) or tympanoplasty for chronic suppurative OM (CSOM).
Diagnosis was recorded at the time of surgery. OME was deﬁned as
the presence of a middle ear effusion (MEE) without symptoms or
signs of suppurative infection [29] for longer than 3 months. rAOM
was deﬁned as at least 3 acute OM presentations within a 6 month
period or 4 presentations in a 12 month period in between which
clinical symptoms resolved. CSOMwas deﬁned as having persistent
discharge from the middle ear for more than 6 weeks through a
perforation of the tympanic membrane [29], however discharge
was resolved prior to surgery. Children were identiﬁed as Aborig-
inal or non-Aboriginal based on parental report.
Approval for this studywas obtained from the PrincessMargaret
Hospital for Children (831EP), Armadale-Kelmscott Hospital and
Osborne Park Hospital Ethics Committees, the Western Australian
Aboriginal Health Information and Ethics Committee and Aborig-
inal Community Controlled Health Organisations in the Kimberley
and Eastern Goldﬁelds regions.
2.1.2. Healthy control cohort
Children aged between 1 and 15 years were recruited through
the Vaccine Trials Group at Princess Margaret Hospital for Children,
Perth, Australia between 2007 and 2009. Children were eligible if
they were healthy, had no history of obstructive sleep disorder, no
history of pneumonia, had less than 2 ear infections in the past 12
months, or less than 3 ear infections ever, no history of chronic or
recurrent sinusitis or rhinitis and no history of previous ear, nose or
throat surgery. Written informed consent was obtained from par-
ents or guardians. Clinical data was collected using parental ques-
tionnaires and from medical records. Approval for this study was
obtained from the Princess Margaret Hospital for Children Ethics
Committee (1385EP).
Exclusion criteria for both cohorts included any chromosomal or
craniofacial disorders, known immunodeﬁciency or receiving
immunosuppressive therapy.
2.2. Sample collection
Saliva was collected from children prior to surgery for the sur-
gical group or at the clinic visit for the healthy controls using jumbo
swabs (Multi-gate, Villawood, Australia) whichwere placed in 15ml
tubes (Sarstedt, Nümbrecht, Germany) for storage at 80 C. Prior
to analysis, swabs were thawed and centrifuged at 3200 g for
15 min at 4 C, saliva was collected and aliquoted. Blood was
collected in a serum clot tube (Vacuette® Greiner Bio-one, Frick-
enhausen, Germany) and centrifuged for 10 min at 3200 g and
serum aliquoted. All aliquoted samples were stored at 80 C until
analysis. For the cases, if MEE was present following an anterior-
inferior myringotomy incision it was collected utilizing a 2ml sy-
ringe and blunt drawing up needle. MEE were transported on ice
within 4 h of collection for culture and PCR.
2.3. Bacteriological culture
MEE samples were cultured using standard techniques. Primary
inoculations of MEE samples were made on blood agar, cysteine
lactose electrolyte deﬁcient agar, Filde's agar and colistin nalidixic
acid (colistin sulphate 7.5 mg/L and nalidixic acid 5 mg/L) blood
agar plates. Plates were incubated at 35 C in 5% CO2 and inspected
for growth at 24 and 48 h. In addition, blood agar plates with
vancomycin (2.5 mg/L) and nalidixic acid (10 mg/L) were used for
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with inspection at 48 h and 7 days. All predominant bacteria were
recorded including normal nasopharyngeal ﬂora.
2.4. Pneumolysin PCR
Genomic DNA was extracted from the MEE specimens using
Roche Total Nucleic Acid Extraction kits (Roche Diagnostics) and
following the manufacturer's instructions. Real time PCR to detect
the ply gene was performed on the extracted DNA as previously
described [30].
2.5. Measurement of IgG and IgA against S. pneumoniae proteins
using a multiplex bead assay
S. pneumoniae proteins PspA1, PspA2, CbpA and Ply were
expressed and puriﬁed, and IgG and IgA antibody titres were
measured by bead-based immunoassay as described previously for
IgG [20]. Brieﬂy, puriﬁed recombinant proteins were covalently
conjugated to activated ﬂuorescent carboxylated microspheres
using a two-step carbodiimide reaction. Pooled sera from adult
volunteers were used as the reference sera, and inter-assay vari-
ability was determined using quality control sera. Test serum
samples were diluted 1:100 (PspA1) or 1:250 (PspA2, CbpA and Ply)
and saliva samples were diluted at 1:10 in phosphate buffered sa-
line (PBS) containing 2% newborn bovine serum and 0.05%
Tween20 (all Sigma-Aldrich). Twenty ﬁve microliters of diluted
sample was incubated with a mixture of 25ml of the protein coated
microspheres for 30 min at room temperature. Plates were washed
with PBS containing 0.05% Tween20 and 100 ml of R-phycoerythrin
conjugated anti-human IgG or IgA were added (Jackson Immu-
noResearch Laboratories, Pennsylvania, USA), before incubation for
30 min at room temperature. Plates were again washed in PBS
containing 0.05% Tween20 prior to analysis. Fluorescence of 100
beads within each bead region was measured on the BioPlex®200
system (Bio-Rad). Mean ﬂuorescence data was collected in real-
time and analysed using Bio-plex Manager 5.0 software. Data in
arbitrary units (AU)/ml were generated from a 5-PL standard curve
of mean ﬂuorescence intensity against the in-house reference sera
and plotted as geometric mean concentration (GMC) with 95%
conﬁdence intervals (CI). Out of range values were repeated using
appropriate higher or lower serum dilutions.
2.6. Total protein assay
To standardise salivary antibody levels across the cohort, total
protein was measured using the Micro BCA Protein Assay Kit
(Thermo Scientiﬁc), following the manufacturer's instructions.
Brieﬂy, saliva samples were diluted 1:30 in a 96 well plate with
phosphate buffered saline. The working solution (25 parts BCA
reagentMA, 24 parts reagentMB and 1 part reagentMC) was added
and incubated at 37 C for 120 min. Plates were cooled to room
temperature and the absorbance measured at 595nm. Blanks were
subtracted and protein concentration was calculated according to
the protein standard curve in mg/ml. Saliva was standardised as AU
per mg of total protein in the saliva.
2.7. Statistical analyses
Host and environmental risk factors were compared between
Aboriginal and non-Aboriginal children with a history of OM and
healthy control children using Student's t tests for continuous
variables (age) and Pearson Chi-square analysis (p-value asymp-
tomatic signiﬁcant 2-sided) for categorical variables (gender and
day-care attendance). Differences in frequencies of diagnoses,surgery and samples below the assay detection limit between the
Aboriginal children and non-Aboriginal children were assessed
using a Chi-square analysis. Serum antibody titres were expressed
as Arbitrary units/mL (AU/mL) against a reference human serum
pool and reported as adjusted antigen-speciﬁc geometric mean
concentrations (GMCs) with 95% conﬁdence interval (CI), adjusting
for confounding variables as appropriate. GMCs were calculated
using adjusted and logged antibody concentrations. Salivary anti-
body titres were calculated as for serum and then adjusted to
correct for differences in salivary stimulation (ie by food or drink
etc) and time of collection by correcting to 1 mg/ml of total protein
in the sample. To compare differences in anti-pneumococcal
(PspA1, PspA2, CbpA and Ply) antibody levels between Aboriginal
and non-Aboriginal children with a history of OM and healthy
control children univariate analysis using a general linear regres-
sion model adjusting for age and day-care attendance was used. To
determine differences in the antibody titres based on Ply PCR
positiveMEE, independent t-tests were used. Paired samples t-tests
were used to determine differences in ratios of IgA to IgG in serum
and saliva. ANOVA with post hoc Tukey was used to assess differ-
ence in mean antibody titres between age categories for each
group. IBM SPSS Statistics 20 for Windows software package (IBM,
New York USA) was used for all statistical analyses and data were
plotted using GraphPad Prism 6 (GraphPad Software Inc, California,
USA).
3. Results
3.1. Study population
One hundred and eighty three children were recruited,
including 36 healthy children who were all non-Aboriginal as well
as 70 Aboriginal and 77 non-Aboriginal children undergoing sur-
gery for OM. None of the healthy control children had any signiﬁ-
cant history of respiratory infection including OM, 74% of the non-
Aboriginal cases and 63% of Aboriginal cases were undergoing
surgery for ventilation tube insertion (Table 1) and 21% and 31% for
myringoplasty respectively (Table 1). The majority of non-
Aboriginal cases had a current diagnosis for surgery of chronic
OME (79%) and/or rAOM (47%) (Table 1). In Aboriginal children,
chronic OME was the most common diagnosis (61%) followed by
CSOM (34%) (Table 1). One non-Aboriginal child was undergoing a
mastoidectomy for mastoiditis. One Aboriginal child and 2 non-
Aboriginal children were diagnosed with cholesteatoma.
Eleven of 56 Aboriginal children and 10 of 73 non-Aboriginal
children with a history of OM had received Prevenar® (data
missing from 14 to 4 children respectively), 12 of the 36 healthy
control children had received Prevenar®. Children were only re-
ported as having up to date immunisations if the parents responded
yes to the question “are your child's immunisations up to date?”
and/or if it was recorded on the Australian Childhood Immunisation
Registry (ACIR). No signiﬁcant difference in immunisation status
was observed between the groups (p ¼ 0.148) (Table 1).
3.2. Culture and PCR for S. pneumoniae from middle ear effusions
One hundred and six MEE from 74 children were cultured, from
these only 2 MEE from 1 non-Aboriginal child was positive for
S. pneumoniae, 5 MEE from 5 children (3 Aboriginal and 2 non-
Aboriginal) were positive for nontypeable Haemophilus inﬂuenzae
and 5 MEE from 3 children (2 Aboriginal and 1 non-Aboriginal)
were positive for Moraxella catarrhalis. Pneumolysin PCR was per-
formed on genomic DNA isolated from 110 MEE from 75 children.
Fourteen (12.7%) MEE from 10 (13.3%) children (2 Aboriginal and 8
non-Aboriginal) were PCR-positive for pneumolysin indicating the
Table 1
Study population.
Healthy children Aboriginal cases Non-Aboriginal cases P -value
Number 36 70 77 NA
Mean age years (range) 8.3 (1.6e14.4) 6.7 (1.7e12.7) 5.0 (1.1e13.6) 0.000
Male 13 (36%) 39 (56%) 39 (51%) 0.199
Have attended day-care 23 (64%) 28 (40%) 43 (56%) 0.290
History of CSOM 0 (0%) 26 (37%) 8 (10%) 0.005
Current surgery NA 44 (63%) 57 (74%) 0.200
VTI Myringotomy NA 4 (6%) 4 (5%) 0.349
Myringoplastya NA 22 (31%) 16 (21%) 0.098
Adenoidectomy NA 1 (1%) 10 (13%) 0.015
Principal diagnosis/es
OME NA 43 (61%) 61 (79%) 0.046
rAOM NA 21 (30%) 36 (47%) 0.020
CSOM NA 24 (34%) 6 (8%) 0.000
Immunisations up to date 36 (100%) 52 (74%) 69 (90%) 0.148
Children who have received Prevenarb 33% 20% 14% 0.093
On antibiotics at enrolmentc 0% 3% 12% 0.021
a Some myringoplasties were performed due to failure of the tympanic membrane healing post-VTI.
b Healthy n ¼ 36, Aboriginal cases n ¼ 56, non-Aboriginal cases n ¼ 73.
c Healthy n ¼ 36, Aboriginal cases n ¼ 65, non-Aboriginal cases n ¼ 75.
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assessed as nasopharyngeal swabs were not collected.
3.3. Age and day-care attendance effected pneumococcal protein
antibody titres and were treated as confounding factors
Confounding factors associated with differences in antibody
levels between the different groups were assessed between
Aboriginal cases, non-Aboriginal cases and healthy controls. Age
had the greatest effect on antibody titres against all antigens in the
serum and saliva (p  0.05), whilst day-care attendance (current or
previous) only appeared to inﬂuence anti-Ply IgA antibody titres
(p ¼ 0.011). Gender and current antibiotic use were demonstrated
to have no effect on antibody titres to any of the antigens tested
(data not shown). All antibody titres reported were therefore
adjusted for age and having ever attended day-care.
3.4. Aboriginal children with OM have higher or comparable serum
IgG and IgA titres to pneumococcal proteins when compared with
both non-Aboriginal children with OM and healthy controls
There was no evidence that Aboriginal children had lower
serum IgG (Fig. 1A) or IgA (Fig. 1B) antibodies to any of the pneu-
mococcal proteins tested. Serum antibody levels were signiﬁcantly
higher in Aboriginal children with OM than in healthy control
children for anti-PspA1 IgA, anti-CbpA IgG and anti-Ply IgG
(p¼ 0.001, p¼ 0.012 and p¼ 0.004 respectively) (Fig. 1). Aboriginal
childrenwith OM also had signiﬁcantly higher serum anti-CbpA IgA
(p ¼ 0.047), and anti-PspA2 IgG, CbpA IgG and Ply IgG antibody
levels than non-Aboriginal children with OM (p ¼ 0.03, p ¼ 0.002
and p ¼ 0.012 respectively). No signiﬁcant differences in serum IgG
and IgA antibody titres for any of the pneumococcal proteins were
observed between non-Aboriginal children with a history of OM
and healthy control children (Fig. 1A and B). Almost all serum
samples had detectable pneumococcal protein-speciﬁc IgG and IgA
antibodies. No serum samples had titres below the limit of detec-
tion in the Aboriginal cases, 1 non-Aboriginal case had IgA below
the limit of detection for PspA2, CbpA and Ply and one healthy
control child had serum IgA below the limit of detection for PspA1
(data not shown).
To determine differences in antibody titres in the optimal age
group for vaccination (0e3 years) versus the older age groups (3e6
years and over 6 years) data were categorised and mean antibody
titres compared using ANOVA. Aboriginal children with OM hadsigniﬁcantly lower antibody titres in the 0e3 year category
compared to the 2 older categories (14994 vs 23116 and 59856 AUs;
p ¼ 0.001) for Ply IgG, but not for any other antibody. Non-
Aboriginal children with OM aged 0e3 years had signiﬁcantly
lower antibody titres for anti-Ply IgA and IgG, and anti-PspA1 IgG
than the older age categories (38 vs 171 and 376 AUs; p ¼ 0.041;
3373 vs 17093 and 67473 AUs; p¼ 0.001; and 341 vs 1376 and 3058
AUs; p < 0.001 respectively). No differences were seen for any other
antibody in the non-Aboriginal children with OM nor for the
healthy controls.3.5. Aboriginal children with OM have higher or comparable
salivary IgA and IgG titres to pneumococcal proteins when
compared with non-Aboriginal children with OM and healthy
controls
Differences were observed between the 3 groups for all salivary
IgA and IgG antibodies measured (Fig. 1C and D). Signiﬁcantly
higher titres of salivary anti-PspA1 IgA (p ¼ 0.004), and salivary
anti-PspA1, CbpA and Ply IgG (p < 0.001, p ¼ 0.001 and p ¼ 0.001
respectively) were observed in Aboriginal cases compared with
healthy controls (Fig. 1). Aboriginal children with OM also had
signiﬁcantly higher salivary antibody titres than non-Aboriginal
children with OM for anti-PspA1, PspA2 and Ply IgA (p ¼ 0.003,
p ¼ 0.001 and p < 0.001 respectively) (Fig. 1 D) and anti- PspA2,
CbpA and Ply IgG (p ¼ 0.001, p ¼ 0.01 and p ¼ 0.022) (Fig. 1C). Only
the salivary anti-PspA1 IgG titres were signiﬁcantly higher in non-
Aboriginal childrenwith a history of OMwhen compared to control
children (p ¼ 0.025).
Differences in the number of responders were compared by
assessing frequencies of salivary samples with antibody titres
within the limit of detection for each group. Differences between all
of the groups were observed (Table 2): CbpA IgG, p¼ 0.004; Ply IgA,
p ¼ 0.001; Ply IgG, p ¼ 0.001; PspA2 IgA, p ¼ 0.005; PspA2 IgG,
p ¼ 0.001; PspA1 IgG, 0.033 except PspA1 IgA (p ¼ 0.061). Non-
Aboriginal children with OM were less likely to have detectable
salivary CbpA IgG (p ¼ 0.002), Ply IgA (p ¼ 0.001) and IgG
(p ¼ 0.002), PspA2 IgG (p ¼ 0.001) and IgA (p ¼ 0.005), and PspA1
IgA (p ¼ 0.018) antibodies than the Aboriginal children (Table 2),
but this was not observed for PspA1 IgG (p ¼ 0.055). More non-
Aboriginal children with OM were non-responders than healthy
controls for Ply IgA (p ¼ 0.042), Ply IgG (p ¼ 0.032), PspA2 IgA
(p ¼ 0.033) and PspA2 IgG (p ¼ 0.011). Aboriginal children with a
history of OM and healthy controls had similar rates of antibodies
Fig. 1. Comparison of antibody titres for serum A) IgA and B) IgG, and salivary C) IgA and D) IgG between healthy children, Aboriginal children with a history of otitis media
and non-Aboriginal children with a history of otitis media. Adjusted (age and day-care attendance) geometric mean concentration of serum IgA and IgG in Arbitrary Units/mL
and salivary IgA and IgG/ml/mg total protein) (95% CI) against pneumococcal proteins in healthy controls (black bar), non-Aboriginal children with a history of OM (grey bar) and
Aboriginal children with a history of OM (hatched bar). P-value determined using linear regression correcting for age and day-care attendance. PspA 1/2, pneumococcal surface
protein A families 1 and 2; CbpA, choline binding protein A; Ply, pneumolysin. *p  0.05; **p  0.01; ***p  0.001.
Table 2
Saliva samples with detectable antibody according to group. 50 children in the
Aboriginal group, 57 in the non-Aboriginal group, 36 Healthy controls. NA - No
salivary IgA is measured for CbpA as it binds the secretory component.
Aboriginal children Non-Aboriginal
children
Healthy controls
IgA IgG IgA IgG IgA IgG
PspA1 100% (50) 44% (22) 89% (51) 26% (15) 94% (34) 19% (7)
PspA2 94% (47) 90% (45) 74% (42) 61% (35) 92% (33) 86% (31)
CbpA NA 100% (50) NA 82% (47) NA 94% (34)
Ply 100% (50) 100% (50) 79% (45) 82% (47) 94% (34) 97% (35)
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both at the mucosal surface and systemically
To investigate the site of production of antibody within the
saliva sample (mucosal antibody or transudation from the serum),
the ratio of IgA to IgG antibody in the serum was compared to that
in the saliva. Alterations of the ratio in the saliva when compared to
that in the serum, would suggest that antibody may have been
locally produced. This could not be performed for CbpA as IgA
cannot be measured in the saliva for this antigen due to the binding
of secretory component [31,32]. Using paired samples t-tests, all
ratios were ﬁrst assessed as an entire cohort (containing all chil-
dren within the study) and then by separating and assessing the
differences between the groups (healthy controls, non-Aboriginal
cases and Aboriginal cases). Differences were observed in theratios between serum and saliva for PspA1, PspA2 and Ply
(p  0.009) suggesting that at least some of the antibody to these
proteins was locally produced at the mucosal surface. The site of
antibody production was also assessed by performing correlations
between serum and salivary IgA (for all proteins except CbpA), and
serum and salivary IgG. Antibody to all proteins had signiﬁcant
positive correlations, ranging from weak to strong
(r¼ 0.331e0.791; p 0.04), both overall and for the individual sub-
groups with the exception of CbpA IgG in the Aboriginal cases
(r ¼ 282; p ¼ 0.09).4. Discussion
In this cross-sectional study, we examined antibody levels for
conserved pneumococcal protein antigens in Aboriginal and non-
Aboriginal children undergoing surgery for OM and healthy non-
Aboriginal controls. This is the ﬁrst report of pneumococcal pro-
tein antibody titres in any Indigenous population. We found no
evidence of impaired pneumococcal antibody titres in Aboriginal
children, in fact overall they tended to have higher mucosal and
systemic antibody levels for the pneumococcal protein antigens
tested compared to both the non-Aboriginal children having sur-
gery for OM and the non-Aboriginal healthy controls (who were
both similar). These ﬁndings for Aboriginal children are similar to
those we reported in young children under the age of 3 years with
rAOM who had higher protein antibody levels compared to age-
matched healthy controls [20]. These high antibody titres may
indeed be protective, given that S. pneumoniae detection in the
middle ears of these children was low. A limitation of this study is
that colonisation could not be assessed as nasopharyngeal swabs
R.B. Thornton et al. / International Journal of Pediatric Otorhinolaryngology 92 (2017) 119e125124were not collected. Previous studies have found that otitis prone
children have lower pneumococcal-speciﬁc antibody responses
[19]. Furthermore Xu et al. showed that otitis prone children who
were colonised with S. pneumoniae and went onto to develop
pneumococcal AOM had lower IgA and IgG mucosal antibody titres
to PhtD, CbpA and Ply (in bothMEE and nasopharyngeal secretions)
at the onset of an S. pneumoniae AOM episode than children who
were colonised but did not develop pneumococcal AOM [33,34].
These deﬁciencies in pneumococcal antigen speciﬁc mucosal im-
mune responses were shown to correlate with an increased sus-
ceptibility to developing OM [34]. Conversely, longitudinal studies
of Finnish children found that antibodies to pneumococcal proteins
including PspA and Ply, were indicators of prior exposure through
carriage and titres did not predict disease susceptibility
[21,23,25,26,35]. The children in this study were aged between 1
and 14 years. While most children develop recurrent AOM and
chronic OME in the ﬁrst few years of life, some children have
persistent disease and ongoing treatment is required throughout
childhood. The older age and high rates of Aboriginal and non-
Aboriginal children who were diagnosed with both OME and
rAOM reﬂects the long history of non-resolving disease in this se-
vere OM cohort. In our previous studies, antigen-speciﬁc antibodies
in younger healthy non-Aboriginal children increased with age
[20]. This same age associated increase was not apparent in a sub-
analysis of the Aboriginal and non-Aboriginal otitis-prone children
during their optimal age for vaccination in this study (0e3 years). A
limitation of this sub-analysis is the small number of children aged
0e3 years for each group (10 and 16 respectively). Longitudinal
studies of pneumococcal carriage and immunity, particularly in
Aboriginal children, are required to determine if antibody to vac-
cine candidates are indeed protective and/or predictive of a sus-
ceptibility to pneumococcal infection.
The presence of mucosal pneumococcal protein antibody sug-
gests that serum IgG crosses into the mucosal space, likely by
transudation, while much of the IgA measured at the surface is
locally produced. IgG is an important part of the mucosal immunity
because unlike IgA it is not susceptible to cleavage by bacterial
proteases [36]. In themouse S. pneumoniae transmissionmodel, it is
IgG not IgA at the mucosal surface that is responsible for the
agglutination and subsequent clearance of the pneumococcus [36].
Currently no data exists demonstrating the functionality of any of
the mucosal protein speciﬁc antibodies in children with OM
(Aboriginal or non-Aboriginal) compared to healthy children. A
study conducted by Short et al., has demonstrated in mice that
mucosal antibody may actually be detrimental, with IgA mediating
the formation of neutrophil extracellular traps in the middle ear,
thereby facilitating development of pneumococcal OM [37]. It may
be that this enhanced mucosal antibody response combined with
host susceptibility to OM enhances the development of chronic ear
disease rather than preventing infection. This needs to be further
explored in populations at high-risk to mucosal pneumococcal
diseases including OM.
A lack of correlation between low antibody titres and enhanced
susceptibility to disease appears to be antigen dependent and dif-
fers between studies. Recent data has shown that compared to
healthy children, those who are otitis prone produce similar levels
of antibody to PhtD, CbpA and Ply at a similar rate, however they
produce less antibody to PhtE and LytB and at a much lower rate
[38]. This antigen speciﬁc deﬁciency may be able to be modiﬁed by
vaccination, however the most appropriate candidates for both the
pathogen and disease process being addressed need to be identi-
ﬁed. A recent study has shown that vaccination of human adults
with PhtD and CbpA elicited an increase in speciﬁc antibody and
that these were protective when administered passively into a
mouse pneumococcal challenge model in a strain dependentmanner [39]. This suggests that protein vaccination does in fact
boost antibody titres to protective levels and may represent an
effective prevention mechanism.
No difference in serum or salivary IgA or IgG antibody levels
were observed based on the Ply PCR positive MEE results. This
likely reﬂects the small sample size however; previous data has
suggested that the antibody titre is highly correlated to nasopha-
ryngeal colonisation [20] rather than middle ear infection.
Previous studies have also suggested that deﬁciencies may exist
in the cellular compartment of the immune response to the com-
mon otopathogens with reduced B cell numbers [40], reduced CD4
T cell responses [41] and numbers [42]. Cellular responses to
S. pneumoniae have not been assessed in this high risk population
and this is an area for further research.
5. Conclusion
Aboriginal children have high antibody titres to pneumococcal
protein antigens in their serum and saliva and it is unlikely that a
deﬁciency in antibody titres to this pathogen is related to their
development of higher rates of OM than their non-Aboriginal
counterparts. Non-Aboriginal children undergoing surgery for OM
have at least as high antibody titres as healthy children with no
signiﬁcant history of any respiratory infection. Thus a deﬁciency in
the ability to mount an antigen speciﬁc antibody response to these
conserved proteins of S. pneumoniae is unlikely to explain their
susceptibility to pneumococcal OM. These data suggest that
Aboriginal children respond to these S. pneumoniae protein anti-
gens and that they represent potential vaccine candidates in
Indigenous populations.
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